This study is currently not recruiting participants.

A Phase 1 Multicenter Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors

Investigating an Investigational Medication for Liver Tumors

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to find out more about talimogene laherparepvec in people with liver tumors that cannot be removed by surgery.

Detailed description of study

The purpose of this study is to find out more about talimogene laherparepvec in people with liver tumors that cannot be removed by surgery.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: liver tumor
  • Age: 18 years - 100 years
  • Gender: All

This study investigates an investigational medication for people with liver tumors that cannot be removed by surgery. Liver tumors are abnormal growths in the liver, and sometimes they cannot be taken out with an operation.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.

  • Who can participate: Adults with liver tumors that cannot be surgically removed may be eligible. Key factors include age 18 or older and specific health criteria related to liver function.
  • Study details: Participants will receive either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1511871819

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team